Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 1. Study design and methodology

Biomarkers

Volumn 20, Issue 6-7, 2015, Pages 382-390

  Ogden, Michael W ^a   Marano, Kristin M ^a   Jones, Bobbette A ^b   Stiles, Mitchell F ^b  

^a RAI Services Company   (United States)

^b R J REYNOLDS TOBACCO COMPANY   (United States)

Author keywords

Biomarkers; compliance; feasibility; health status measures; multi center randomized study; risk continuum

Indexed keywords

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLIANCE (PHYSICAL); CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SMOKELESS TOBACCO; SMOKING; STUDY DESIGN; TOBACCO; CLINICAL TRIAL; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SMOKING CESSATION; TIME FACTOR; UTILIZATION;

NICOTINE GUM;

ADULT; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; SMOKING; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TOBACCO USE CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO, SMOKELESS;

EID: 84948719915     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1094133     Document Type: Article

References (13)

1. American Thoracic Society (ATS). (1991). Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 144: 1202-18
2. Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. (2012). The chemical composition of smokeless tobacco: a survey of products sold in The United States in 2006 and 2007. Regul Toxicol Pharmacol 64: 367-87
3. Federal Trade Commission (FTC). (1967). Cigarettes: testing for tar and nicotine content. Federal Register 32: 11178. August 1
4. Federal Trade Commission (FTC). (1980). Cigarettes and related matters: carbon monoxide, tar and nicotine content of cigarette smoke; description of new machines and methods to be used in testing. Federal Register 45: 46483. July 10
5. Ferris BG. (1978). Epidemiology standardization project (American Thoracic Society). Am Rev Respir Dis 118: 1-120
6. International Conference on Harmonization (ICH). (1996). Guidance for industry E6 good clinical practice: consolidated guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf [last accessed 2 Aug 2014].
7. King B, Dube S, Kaufmann R, et al. (2011). Vital signs: current cigarette smoking among adults aged ≥18 years-United States, 2005-2010. MMWR 60: 1207-12
8. Nutt DJ, Phillips LD, Balfour D, et al. (2014). Estimating The harms of nicotine-containing products using The MCDA approach. Eur Addict Res 20: 218-25
9. Ogden MW, Marano KM, Jones BA, et al. (2015a). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 2. Biomarkers of exposure. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094134
10. Ogden MW, Marano KM, Jones BA, et al. (2015b). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 3. Biomarkers of biological effect. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094135
11. United States Congress. (2009). Family smoking prevention and tobacco control act. Available from: http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm237092.htm [last accessed 14 Aug 2014].
12. World Medical Association (WMA). (2002). Declaration of Helsinki-ethical principles for medical research involving human subjects. Available from: http://www.fda.gov/ohrms/dockets/dockets/06d0331/06D-0331-EC20-Attach-1.pdf [last accessed 14 Aug 2014].
13. Zeller M, Hatsukami D., Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in The US. Tob Control 18: 324-32